The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2024 | FLOWERS: osimertinib and savolitinib in MET aberrant, EGFRm NSCLC
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, gives an overview of the Phase II FLOWERS trial (NCT05163249), which assessed osimertinib with or without savolitinib, a c-Met inhibitor, in patients with MET aberrant non-small cell lung cancer (NSCLC). Patients with EGFR mutations (EGFRm) were additionally enrolled, unlike in the Phase II LUMINOSITY trial (NCT03539536). Addition of savolitinib resulted in clinically meaningful improvement. This interview took place at the 2024 World Conference on Lung Cancer (WCLC) in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
